CNNMoney.com
Companies Economy International Corrections Pre-market Trading After-hours Trading Winners/Losers/Actives Bonds Currencies Commodities World Markets Money Magazine Real Estate Taxes Jobs Ask the Expert Money 101 Autos Mutual Funds The Help Desk Loan Center Best Places to Live Ask the Expert Ultimate Guide to Retirement Retirement Calculators Best Funds Best Places to Retire Fortune Brainstorm Tech Apple 2.0 Blog Big Tech Blog Sectors and Stocks Tech Talk Resource Guide Small Business Makeovers Questions & Answers Small Business Video 100 Best Places to Launch FSB 100 Fortune Small Business Fortune 500 Brainstorm Tech Investing Management C-Suite Rankings Main Create Portfolio Edit Portfolio Create Alerts Edit Alerts

Genentech fails to impress

Investors expecting more when the biotech lifts its forecast send its stock down.

EMAIL  |   PRINT  |   SHARE  |   RSS
 
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Aaron Smith, CNNMoney.com staff writer

NEW YORK (CNNMoney.com) -- Genentech's stock fell after the biotech raised its 2008 earnings guidance, but not enough impress investors.

The California-based company lifted its annual forecast Friday to between $3.35 and $3.45 per share from previous guidance of $3.30 to $3.45 per share. Despite the increase, Genentech's (DNA) stock fell 4% in afternoon trading.

Eric Schmidt, a biotech analyst for Cowen & Co. who attended the biotech's analyst meeting in New York Friday, said the sell-off stemmed from investors who expected the company to raise the high end of its range.

Much of this expectation was based on the Food and Drug Administration's recent nod to Genentech's Avastin drug.

On Feb. 22, the FDA approved Avastin for breast cancer, a surprise move that drove up the stock 13% in the following weeks. In December of 2007, an FDA advisory panel had voted 5-4 against Avastin, saying that the safety risks did not outweigh the benefit

David Ebersman, chief financial officer for Genentech, said the guidance move should not have been a surprise, since the biotech previously said that Avastin approval would be required to push guidance "to the upper end of the range."

Avastin is already one of Genentech's top sellers as a treatment for lung and colorectal cancer, with sales totaling $3 billion in 2007.

Genentech is the world's largest biotech in terms of market capitalization. Amgen (AMGN, Fortune 500), also based in California, is the world's largest biotech in terms of annual sales. To top of page

Features
  • 091020_nuclear_0154.04.jpg
    Minimum wage to $20 an hour. That's what Sally Delk hopes for with a job at the nuclear power plant.  More
  • charlotte_then_now.gi.04.jpg
    Charlotte Street was the epicenter of urban blight. No longer. Now Bimmers and boats fill driveways. More
  • excon-pic-2.04.jpg
    Ex-convicts like Gregory Headley are 'at the back of the line' in the struggle to find work.  More
  • package.gi.04.jpg
    Steve Jobs revived Apple, defying the worst economic conditions since the Great Depression. More
  • droid.04.jpg
    Consumers looking to buy electronics for holiday gifts won't have to break the bank this season. More
  • airport_luggage.ju.04.jpg
    Search firm says it will pay the bill for wireless Internet during the holidays. More
  • twitter_screenshot.04.jpg
    Twitter and LinkedIn hook up, signing agreement to let users share information across both platforms. More
Markets Last Change
Dow Jones 10,270.47 73.00 / 0.71%
Nasdaq 2,167.88 18.86 / 0.88%
S&P 500 1,093.48 6.24 / 0.57%
10-year Bond 99 19/32 Yield: 3.42%
U.S.Dollar 1 euro = $1.496 0.004
November 13, 2009 4:01 PM ET
CompanyPrice% Change
YRC Worldwide Inc 1.12 22.53%
Blockbuster Inc 0.76 -8.46%
Dollar General Corp 22.64 7.81%
JC Penney Co Inc 31.34 6.63%
Nov 13 3:53pm ET †
6 double dip warning signs The recovery from the Great Recession has likely started. But many economists are worried about falling into another downturn. Here's what has them concerned. More
America's Money: In their own words Across the nation, the deepening economic downturn is fueling anxiety among everyday folks. See what's got them worried and how they're coping. More
Pieces of Madoff Many of Bernie Madoff's victims wanted a piece of the felonious financier. This week they could get one: Hundreds of his and Ruth's possessions went up for auction Saturday and they fetched nearly $1 million, a lot more than expected. More

Sponsors

© 2009 Cable News Network. A Time Warner Company. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy
Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.